EBR/BIOS (EBR/BIOS)

Euronext Brussels: EBR/BIOS · EUR

€0.00

+0.00 (0.0%)· Recorded snapshot

Market cap	1.3M
Revenue (ttm)	-2.6M
Net income (ttm)	-6M
EPS (ttm)	-€0.01
Shares out	652.9M
Beta	-1.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): -2.6M
Net income (ttm): -6M
EPS (ttm): -€0.01
Market cap: 1.3M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-107.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EBR/BIOS indicators

Market & fundamental data

Available fields

142

Groups with data

Currency

EUR

Showing 142 of 142 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	Belgium
Country code	BE
Earnings date	2026-12-24
Employees	7
Employees change	5
Employees growth	250%
Enterprise value	EUR 3.7M
Exchange	Euronext Brussels
Financial currency	EUR
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Industry	Biotechnology
Is primary listing	Yes
ISIN number	BE0974280126
Last earnings date	2025-10-27
Last refreshed	2026-10-29
Market cap	EUR 1.3M
Next earnings date	2026-12-24
Price	EUR 0.00
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ebr/BIOS
Website	https://www.biosenic.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-649.55%
FCF / EV yield	-33.45%
FCF yield	-96.04%
Industry P/E	29.06x
Sector forward P/E	22.86x
Sector P/E	29.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	210.15%
Pretax margin	299.81%
Profitable quarters	1
Profitable years	1
ROA	-49%
ROCE	192.81%
ROIC	-107.78%
SBC / revenue	-2.43%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	2
FCF growth (QoQ)	109.77%
Net income growth quarters	1
Net income growth years	2
OCF growth (QoQ)	109.77%
Revenue growth	-69.64%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR 0
Depreciation and amortization	EUR 330,500
EBIT	EUR -5.4M
EBITDA	EUR -5.1M
EPS	EUR -0.01
FCF per share	EUR -0.00
Financing cash flow	EUR 927,000
Free cash flow	EUR -1.3M
Free cash flow minus SBC	EUR -1.3M
Gross profit	EUR -3.1M
Investing cash flow	EUR 60,000
Net borrowing	EUR 950,000
Net cash flow	EUR -268,000
Net income	EUR -6M
Operating cash flow minus SBC	EUR -1.3M
Operating income	EUR -5.4M
Revenue	EUR -2.6M
Stock-based compensation	EUR 63,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-29.66
Book value per share	EUR -0.04
Interest coverage	-6.09
Long-term assets	EUR 1.8M
Long-term liabilities	EUR 24.4M
Net cash (debt)	EUR -23M
Net cash / market cap	-1,763.54%
Piotroski F-Score	4
Property, plant and equipment	EUR 2,000
Shareholders' equity	EUR -23.6M
Tangible book value	EUR -23.6M
Tangible book value per share	EUR -0.04
Total assets	EUR 4.5M
Total cash	EUR 501,000
Total debt	EUR 23.5M
Total liabilities	EUR 28.1M
WACC	2.61%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	EUR 2.7M
Current liabilities	EUR 3.7M
Current ratio	0.53
Net working capital	EUR -1.2M
Quick ratio	0.5
Working capital	EUR -3.5M
Working capital turnover	0.71

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-166.54%
Shareholder yield	-166.54%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 0.00
1D price change	0%
1Y price change	-13.04%
1Y return CAGR	-13.05%
1Y total return	-13.04%
20-day SMA	EUR 0.00
200-day SMA	EUR 0.00
3Y price change	-95.95%
3Y return CAGR	-65.65%
3Y total return	-95.95%
50-day SMA	EUR 0.00
50-day SMA vs 200-day SMA	50under200
52-week high	EUR 0.00
52-week high date	2026-03-02
52-week low	EUR 0.00
52-week low date	2026-05-05
6M price change	-9.09%
6M total return	-9.09%
All-time high	EUR 0.35
All-time high date	2022-10-27
All-time low	EUR 0.00
All-time low date	2025-04-24
Average true range (ATR)	EUR 0.00
Average volume	0
Beta (1Y)	0.3
Beta (2Y)	0.19
Beta (5Y)	-1.58
Change from 52-week high	-23.08%
Change from 52-week low	11.11%
Change from all-time high	-99.43%
Change from all-time low	66.67%
Monthly RSI	34.16
Previous close	EUR 0.00
Price vs 150-day SMA	-4.76%
Price vs 20-day SMA	0%
Price vs 200-day SMA	-4.76%
Price vs 50-day SMA	0%
Relative volume	0.27
RSI	39.35
Sharpe ratio	-0.03
Sharpe ratio (3Y)	-0.43
Sortino ratio	0.06
Sortino ratio (3Y)	-0.66
Weekly RSI	38.82
YTD price change	-13.04%
YTD total return	-13.04%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	603.2M
Shares change (QoQ)	0%
Shares outstanding	652.9M

Deeper analysis on EBR/BIOS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this EBR/BIOS report

Is a complete EBR/BIOS research report available?

No complete published report is available for ebr/BIOS (EBR/BIOS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

EBR/BIOS (EBR/BIOS)

Price

Financial snapshot

Fair-value bridge

Latest news · EBR/BIOS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All EBR/BIOS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on EBR/BIOS

Frequently asked questions